20d agoSeeking AlphaBULLISH 67Analyst
BBH: Biotech's Next Growth Cycle Is Just Getting Started
Buy VanEck Biotech ETF (BBH) for concentrated biotech exposure—Amgen, Gilead, Vertex lead strong pipelines and upside; see why it may beat S&P 500.
Archived explainer. For the current picture see today's GILD page.
Why Is GILEAD SCIENCES INC (GILD) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 24, 2026 at 2:40 PM ET · reviewed against 7 wire stories
GILEAD SCIENCES INC (GILD) is drawing unusual attention today. Our newswire has captured 7 stories on GILD across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
GILD stock is moving modestly higher in early trading following the European Commission’s approval of Gilead’s Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. The approval expands the drug’s role in Europe and comes amid strong performance in Gilead’s HIV business and broader commercial momentum across its oncology and liver disease divisions.
What Happened
The European Commission granted marketing authorization for Gilead’s Trodelvy plus Merck’s Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer. This follows a Phase 3 ASCENT-04 study showing a 35% lower risk of progression or death for patients receiving the combination. The approval is a significant milestone for Gilead’s oncology portfolio, which has treated more than 75,000 breast cancer patients globally with Trodelvy. The move adds to recent positive developments for the company, including strong fiscal Q2 2026 results with total revenue rising 10% year over year to approximately $7.8 billion.
What The Data Shows
GILD opened with a +0.5% gap from the prior close and reached an intraday high of $147.00 before retreating to $146.44 in late morning trading. Volume has been subdued at 1.3 million shares, or 0.2 times the 3-month daily average. The stock remains within its 52-week range of $108.46 to $157.29. On the fundamentals, Gilead has a market cap of $181.2 billion, with unprofitable earnings (TTM EPS -2.61), revenue up 5.5% TTM, and a net margin of -10.6%. The stock’s beta of 0.34 indicates low volatility relative to the market.
What To Watch
Gilead’s upcoming earnings report will be a key event for investors. Until then, the broader biotech sector and coverage of its HIV and oncology pipelines will be important to monitor.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GILD by the numbers
Coverage: 7 stories / 4 sourcesAI sentiment: 66/100 (bullish)Mkt cap: $181.2B52w: $108.46 to $157.29
The headlines behind the move
20d agoSeeking AlphaBULLISH 73Product/PR
EU approves Gilead’s Trodelvy combination with Keytruda for first-line breast cancer
European Commission approves Gilead’s Trodelvy + Merck’s Keytruda for first-line PD-L1+ metastatic triple-negative breast cancer in Europe—read the update.
20d agoThe FlyBULLISH 73Product/PR
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
20d agoStockTitanBULLISH 73Product/PR
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
The Phase 3 ASCENT-04 study found a 35% lower risk of progression or death; Trodelvy has treated more than 75,000 breast cancer patients globally.
20d agoYahoo TopBULLISH 67Earnings
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?
Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, including Biktarvy and the newly launched Yeztugo. Gilead also raised its full-year product-sales guidance following the quarter. However, HIV products generated […]
20d agoYahoo TopNEUTRAL 53Earnings
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion. Yet, the income statement tells a considerably less flattering story. Gilead […]
20d agoYahoo TopBULLISH 56General
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday’s blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer’s (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GILD: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GILD move explainers: 2026-08-24